demonstrated to be upregulated in macrophages after tailfin injury in a zebrafish model (31).
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Here, we demonstrate that this injury induced upregulation of macrophage tnfa:GFP is also been implicated in all stages of TB infection, however the cell types involved in vivo have been difficult to observe (53). We used the tnfa BAC promoter GFP line to establish the onset (at 1 day post infection, dpi), and after granuloma formation (at 4dpi) ( Figure 1B ). other tnfa promoter driven line, (Tg(tnfa:eGFP-F)ump5Tg, crossed to Tg(mpeg1:mCherry-
F)ump2Tg) ( Figure S1 ). Our data demonstrate that injury and Mm induced tnfa expression 2 5 2 occurs in macrophages as part of an early M1 response.
5 3
Hif-1α can be stabilised in zebrafish both genetically and pharmacologically using whether Hif-1α promotes M1 polarisation using the tnfa:GFP BAC transgenic line as a readout of M1 macrophages (31, 32). Hif-1α was stabilised genetically in larvae using DA inhibitor that stabilises Hif-1α via inactivation of regulatory prolyl hydroxylase enzymes) was 2 6 3 used to stabilise endogenous levels of . DMOG treatment upregulated expression 45, 46). During both homeostasis and disease physiology, Hif-1α stability is regulated by 2 6 8 microenvironmental hypoxia. To simulate this we subjected the tnfa:GFP line to 5% oxygen 2 6 9
for 6 hours at 32hpf and looked for GFP expression at 48hpf. This level of hypoxia was ( Figure S2 ) (33). Six hours of 5% oxygen increased tnfa:GFP expression at 48hpf,
compared to normoxic controls, to a similar level as that observed with genetic or pharmacological Hif-1α stabilisation ( Figure 1J ). Together, these data indicate that tnfa
expression is part of a pro-inflammatory M1 macrophage response to hypoxia and stabilised
Hif-1α, a response that is targetable by pharmacological agents and has the potential to aid
the host response to bacterial challenge. was significantly abrogated to basal levels by both SC560 and NS398 (Figure 2A -B). We indicate that Hif-1α-induced tnfa expression is caused by a product of the cyclooxygenase regulation of M1 pro-inflammatory cytokines by Hif-1α stabilisation.
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We next tested whether injury-and infection-induced tnfa are cyclooxygenase 2 9 4 dependent processes. Macrophage tnfa:GFP expression induced after injury was not abrogated by cyclooxygenase inhibition using NS398 ( Figure 2D -E). Similarly, cyclooxygenase inhibition using either SC560 or NS398 did not alter the expression of Mm-
induced tnfa:GFP ( Figure 2F -G). Our data indicate that macrophage tnfa expression can be driven by the presence of DAMPS (injury) or PAMPS (Mm) and that these are cyclooxygenase independent mechanisms ( Figure 2H ). pharmacological Hif-1α stabilisation were additive to the tnfa:GFP expression caused by demonstrated that Hif-1α-induced tnfa requires cyclooxygenase activity in Figure 2A -C).
Neither SC560 nor NS398 mediated inhibition of Hif-1α-induced tnfa expression diminished increased by Hif-1α stabilisation and that cyclooxygenase mediated early priming of tnfa in
macrophages is not required for the Hif-1α mediated reduction of bacterial burden. Blocking cyclooxygenase independent arachidonic acid pathways does not abrogate
Hif-1α upregulation of tnfa:GFP
To investigate whether the effect of the cyclooxygenase inhibitors on tnfa was
specific to the prostaglandin path of the arachidonic acid pathway, we targeted the lipoxin
and leukotriene producing arms using the 15-Lipoxygenase inhibitor PD146176 and as DA Hif-α ( Figure 3A -B). PD146176 also did not affect tnfa:GFP expression after Mm PD146176 was sufficient to decrease Mm burden, but not to the same extent as DA Hif-1α
( Figure 3C ). Leukotriene B4 inhibition, using the BLTR1/2 antagonists U75302 and prostaglandins. The best characterised of these as a regulator of macrophage function is
prostaglandin E2 (PGE2). We tested whether PGE2 was a mediator in the HIF/COX/TNF pathway by addition of exogenous PGE2 to DA Hif-1α larvae. Exogenous PGE2 had no However, PGE2 was able to rescue the decrease in tnfa:GFP expression after Cox-1 ( active prostaglandin E2 ( Figure 4G ). The HIF-COX-TNF axis is conserved in human macrophages
To translate our findings from zebrafish to humans we tested whether HIF-1α
stabilisation in human macrophages induces TNF expression. We found that human (0.8% oxygen) than those in normoxia, measured by an anti-human TNF ELISA ( Figure 5A ). Furthermore, treatment with the COX-2 inhibitor, NS398, reduced this hypoxia-induced TNF back to the equivalent levels found in normoxia ( Figure 5A ). This was replicated when HIF- 1α was stabilised in hHDMs using the hypoxia mimetic FG4592 ( Figure 5B ). These data
indicate that the HIF/COX/TNF axis is a conserved mechanism in human macrophages and
could be important in human disease. macrophage phenotypic outcomes will identify potential novel therapeutic avenues for
control of macrophages during disease. Currently, the mechanisms and molecular cues
leading to different macrophage phenotypes are not well-defined in vivo.
Here we show that a disease relevant microenvironmental cue, hypoxia signalling via
Hif-1α, upregulates macrophage tnfa expression in a cyclooxygenase dependent manner in
vivo. TNF regulation by hypoxia has been shown in a range of mammalian cells, and its
promoter region contains HIF responsive elements (HREs), resulting in some level of direct regulation by HIF-1α (60-63). We observed an M1 pro-inflammatory tnfa response with
stabilised Hif-1α, demonstrating that hypoxia signalling alone can lead to a switch of concerning il-1β activation (33). Not only could tnfa activation be achieved by genetic
stabilisation of Hif-1α, but also using hypoxia mimetics and physiological hypoxia. These
findings indicate that the Hif-1α pro-inflammatory switch is targetable by pharmaceuticals
and could be druggable during disease. Hypoxic regulation of TNF via COX has previously
been demonstrated in mammalian osteoblasts, however, little is known about this interaction 3 7 7
(26). Our data demonstrate that Hif-1α upregulation of macrophage tnfa is dependent on cyclooxygenase and further shows that the mechanism is likely to be via the production of PGE2. The degradation metabolite 15-keto-PGE2 did not rescue the loss of tnfa expression 3 8 0 after cyclooxygenase inhibition, consistent with previous reports that 15-keto-PGE2 is widely studied in human, mice and zebrafish and is rich in pro-inflammatory cytokine 3 8 7
production (32, 33, (65) (66) (67) (68) (69) . Here, we observed that an M1 pro-inflammatory tnfa response advantage of using fluorescent transgenic zebrafish lines, such as tnfa:GFP, is that they
enable identification of the cell type producing the transgene in an intact organism. This is
especially important when studying early innate immune cell interactions with pathogens, as
it eliminates the risk of activation during a sorting process. TNF is required for the control of therapies for immune diseases such as Crohn's disease and rheumatoid arthritis, which
have proved effective treatments for these debilitating illnesses, have an associated it has been widely demonstrated that Tnfa is required for control of early infection, with tnfa was downregulated by cyclooxygenase inhibition, there was no effect on the decrease Our data reveal a novel mechanism of TNF activation in macrophages via a Hif-1α/ infections such as TB that might be influenced by a HIF-1α mediated M1/TNF switch.
Hypoxia is a key hallmark of cancers with high levels of HIF-1α widely found in those that
produce large tumours where the centre is hypoxic (78). This is also true of HIF/COX/TNF mechanism. The zebrafish larvae is small enough to be fully oxygenated at 4 3 6 the 2-5dpf stages of this study (81). Further investigation of the HIF/COX/TNF axis in models
where hypoxia is a key hallmark of disease pathology is required to uncover the full 4 3 8 therapeutic relevance of this potentially important novel macrophage pathway.
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In conclusion, we have identified a novel mechanism for macrophage tnfa Mechanism. PLoS Pathog 9(12):e1003789. Inhibitor. Mol Pharmacol 79(6):910-920. peroxisome proliferator-activated receptor gamma (PPAR-γ) to promote C. Model Mech 4(4):526-536. necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting SEM, n=24 cells from 4 embryos accumulated from 2 independent experiments. prevents Hif-1α upregulation of tnfa, an effect rescued by endogenous PGE2. biological repeats from 3 donors. 
